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Abstract
A theoretical model for the intraperitoneal (i.p.) delivery
of cisplatin and heat to tumor metastases in tissues
adjacent to the peritoneal cavity is presented. The pe-
netration distance (the depth to which drug diffuses
directly from the cavity into tissues) is predicted to be
on the order of 0.5 mm. The model shows that ex-
change with the microvasculature has more effect than
cellular uptake in limiting the penetration distance.
Possible effects of hyperthermia are simulated, includ-
ing increased cell uptake of drug, increased cell kill at a
given level of intracellular drug, and decreased micro-
vascular density. The model suggests that the exper-
imental finding of elevated intracellular platinum levels
up to a depth of 3 to 5 mmwhen drug is delivered i.p. by
a heated infusion solution is due to penetration of heat
to this distance, causing increased cell uptake of drug.
Beyond a depth of about 0.5 mm, the drug is delivered
mainly through the circulation. Use of sodium thio-
sulfate to deactivate systemic cisplatin may therefore
be counterproductive when heat is delivered locally.
The model suggests that i.p. delivery of heat, combined
with systemic delivery of drug, may be as effective as
i.p. delivery of heat and drug.
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Introduction
Intraperitoneal (i.p.) delivery of chemotherapeutic drugs
such as cisplatin was developed for diseases such as
ovarian carcinoma, which metastasize mainly in the perito-
neal area. Inconsistent results have been obtained in clinical
trials that compared this therapy to intravenous (i.v.) deliv-
ery. Alberts et al. [2] reported that i.p. therapy gave superior
clinical results compared to i.v. therapy, but Polyzos et al.
[52] were not able to reproduce this finding. Because results
have been mixed, researchers have looked to regional
hyperthermia as a way to improve i.p. therapy. Leopold
et al. [37], using external radiation to achieve locally elevated
temperatures, were able to achieve a mean temperature of
only 40.7jC, which they viewed as insufficient to achieve
successful enhancement of therapy. More recently, the
technique of continuous hyperthermic peritoneal perfusion
has been introduced to overcome this problem. Steller et al.
[58] performed a pilot Phase I trial, and were able to achieve i.p.
temperatures of 41jC to 43jC, whereas Bartlett et al. [3], in
another Phase I trial, reported 42jC to 43jC. Clinical success in
one case of malignant mesothelioma of the peritoneum was
reported by de Bree et al. [8], and Park et al. [50] also found
encouraging results for this disease. More recently, Takahashi
et al. [60] reported that intraoperative hyperthermic peritoneal
lavage was clinically beneficial for gastric cancer.
The rationale for using i.p. therapy is that it allows selective
delivery of cisplatin to tissues adjacent to the peritoneal cavity.
Such tissues may receive drug both from the peritoneal cavity
and from the vascular system. The extent of selective delivery
is conveniently expressed as penetration distance, which may
be defined in several different ways. Van de Vaart et al. [62]
defined penetration distance as the depth from the peritoneal
cavity surface into the tissues within which drug concentration
at a given time point, as measured by the number of platinum–
DNA adducts, is greater than that in control cells distant from
the peritoneal cavity. An alternative definition [40] is the dis-
tance within which the concentration of drug is significantly
higher with i.p. therapy than would be achieved if an amount of
drug resulting in the same plasma area under the concentra-
tion–time curve (AUC) was delivered intravenously. In the
present study, penetration distance is defined as the distance
at which the peak concentration first approaches its plateau
value to within 1% deviation. Regardless of which definition of
penetration distance is used, it is clear that beyond this
distance, i.p. delivery is not necessarily more advantageous
than i.v. delivery. Los et al. [40] sectioned rat peritoneal tissue
168 hours after i.p. and i.v. exposures and found that drug
levels were elevated with i.p. delivery relative to i.v. up to a
distance of only 1.5 mm from the peritoneal surface. Metasta-
ses greater than this size would presumably not receive higher
drug exposure from i.p. therapy. Polyzos et al. [52] speculated
that the size of metastases is a factor determining whether i.p.
therapy is more effective than i.v. therapy.
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In studies combining hyperthermia with i.p. delivery, the
rationale has been that use of hyperthermia enhances the
penetration of drug from the i.p. space [3,5,58,62]. Appar-
ently supporting this assumption, van der Vaart et al. [62], in
a clinical trial on ovarian cancer patients, found that plati-
num–DNA adduct levels were elevated at a depth of 3 to
5 mm into tumor nodules, compared to control levels deter-
mined from buccal cells, which received only systemic
exposure. In this case, the heat was delivered locally by
infusing the peritoneal cavity with perfusate at an elevated
temperature, and the elevation of adduct levels may actually
reflect the penetration distance of heat, as discussed below.
The overall goal of the present study is to estimate the
penetration distance of intraperitoneally delivered cisplatin
into surrounding tissues, and to predict the effects of hyper-
themia on the penetration distance. A previous theoretical
model for drug penetration distance in i.p. therapy was
presented by Dedrick and Flessner [10], who estimated the
penetration distance as (D/k)1/2, where D is drug diffusivity
and k is a first-order rate constant describing blood uptake by
microvessels in the tissues. This estimate neglects several
potentially significant effects. Penetration may be limited by
cellular uptake of drug, in addition to microvascular uptake.
Because cellular uptake is nonlinear, it cannot easily be
described by a first-order rate constant. With time, drug
levels build up in the circulation and the concentration
difference driving transport across the microvessel wall
decreases. Finally, the concentration in the peritoneal cavity
is not a constant as assumed in the estimate of Dedrick and
Flessner [10] but decreases with time. Although some of
these factors were considered subsequently in more detailed
theoretical modeling of Flessner et al. [19], their model was
developed primarily for sucrose, and therefore did not incor-
porate particular properties of cisplatin such as cell uptake
kinetics and peritoneal cavity half-life. These factors are
considered in the model presented below, which is devel-
oped specifically for cisplatin.
Several mechanisms can be proposed by which hyper-
thermia might alter the penetration distance of cisplatin from
the peritoneal cavity into tissues. One possibility is that
hyperthermia increases transport parameters such as drug
diffusivity in tissues or hydraulic conductivity of tissues.
Alternatively, hyperthermia may change the cellular uptake
of drugs; however, because studies have shown that uptake
is increased with heat, this would actually lead to decreased
penetration. A further possibility is that at high temperatures,
tissue perfusion or microvascular surface density changes. A
decrease in microvascular surface density could lead to less
uptake of drugs by microvessels, which would tend to in-
crease the penetration distance, whereas an increase would
have the opposite effect. Hyperthermia also appears to cause
higher cytotoxicity for the same amount of extracellular drug
exposure. Although this effect could lead to cell kill extending
a greater depth into tissues, this is not due to increased
penetration of cisplatin, but to the penetration of heat.
In the present study, a theoretical model for i.p. delivery of
cisplatin in rats is developed. Themodel is used to predict the
penetration distance of the drug from the peritoneal cavity
into the tissues. The penetration distance of hyperthermia
delivered by infusing heated solutions into the peritoneal
cavity is estimated. Possible effects of hyperthermia on drug
transport, including increased cellular uptake and cytotoxicity
and reduced microvascular density, are considered. Also,
the effect of deactivating cisplatin in plasma using sodium
thiosulfate is simulated. This approach has been used ex-
perimentally to reduce systemic exposure and associated
host toxicity [3,11,23].
Materials and Methods
Cellular Pharmacodynamics
A mathematical model of mass transport near the perito-
neum was developed to predict the concentration of cisplatin
in the tissues adjoining the peritoneum as a function of time.
Parameter values were chosen for the rat, based on avail-
ability of pharmacokinetic data for this species. The applica-
bility of the model for humans was also considered. The
penetration of the drug into tissues depends on the rate of
cellular uptake, which is assumed to be described by the
cellular pharmacokinetic model of El Kareh and Secomb [13]:
dc1
dt
¼ k1ce  k V1ci ð1Þ
dck
dt
¼ k2c1  k3ck ð2Þ
where ce is the extracellular concentration of free platinum,
and ci and ck are the intracellular concentrations of total
platinum and DNA-bound platinum (the species responsible
for cell kill), respectively. Experimental methods measure
intracellular platinum levels rather than cisplatin levels, and
cisplatin forms other active platinum species. All concentra-
tion variables in the model are assumed to refer to ultra-
filterable platinum (i.e., platinum either in the form of cisplatin
or its low-molecular-weight metabolites). Values for the
parameters k1, k1V, k2, and k3 were derived [13] by fitting
experimental data [38] for ovarian cancer cells. Values and
sources of all model parameters are given in Table 1.
Cytotoxicity is described by the following pharmacodynamic
model [13]:
S ¼ 1
1þ Aðcpeakk Þm
ð3Þ
where S is survival fraction, and ck
peak is the peak value (over
time) of ck. The parameter A cannot be estimated because
data on bound intracellular concentration are not available. A
value A = 1 was therefore assigned [13], and the absolute
levels of ck are undetermined. Predicted values express
relative changes only.
Simulation of Drug Transport into Tissues
Because drug penetration distance is small [40], the
peritoneal surface can be approximated by a plane. The
transport of cisplatin into the tissues is then governed by:
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Bce
Bt
¼ D B
2ce
Bx2
 1 /
/
ðk1ce  k V1ciÞ
 PSv
/
ðce  cbÞ ð4Þ
where x represents distance into the tissues starting at the
peritoneal cavity surface, t is time, D is the diffusivity of
cisplatin in tissues, and / is the volume fraction of extracel-
lular space in the tissues. The factors (1  / )// and 1// are
included to account for the fact that intracellular concentra-
tion is expressed as micrograms Pt per milliliter of intracel-
lular space, and extracellular concentration as micrograms
Pt per milliliter of extracellular space.
The concentration in the peritoneal cavity as a function of
time, cip(t ), was obtained from Figure 4 of Los et al. [40], with
linear interpolation between the given data points. These
data were used to predict the concentration of platinum in the
plasma, cb(t ), using the following equation:
dcb
dt
¼ PSV
Vd
AP m
d
0
ðce  cbÞdx  kbcb þ Flym
Vd
c ipðtÞ ð5Þ
where P is the microvascular permeability, Sv is the surface
area of perfused microvessels per unit volume of the tissue
surrounding the peritoneum, Vd is the volume of distribution
of cisplatin in plasma, and Flym is the rate of lymph flow
directly from the cavity into the plasma. The integral repre-
sents uptake by the microcirculation from the region that
is supplied directly from the peritoneal cavity. The distance y
is defined by the point at which the spatial derivative of ce is
less than a small fraction of its maximum value. This ensures
that the region of integration includes all tissues that are
significantly affected by drug transport from the peritoneal
space. The constant kb describes the rate of platinum
clearance from the blood by tissues throughout the body.
The predictions of this model were compared with experi-
mental data [40].
Values of Vd and kb were obtained from a study of
pharmacokinetics of cisplatin in humans with i.v. administra-
tion [51]. The value of the volume of distribution, which
depends both on total blood volume and on the extent of
binding of the drug to plasma proteins or other plasma
components, was assumed to scale primarily with body
weight (Table 1). Based on the findings of Dedrick [9] that
the half-life of methotrexate showed only weak dependence
on body weight (slope 0.2), the value of kb of Patton et al. [51]
was assumed to apply also to the rat. Values of Sv, P, and /
that were measured in some (nontumor) tissues lining the
peritoneum were used. Because the peritoneum consists of
several different tissue types, it is possible that these param-
eters vary from one location to another—an effect that is
Table 1. Model Parameters.
Symbol Description Value Source
MWcis Molecular weight of cisplatin 300 –
MWPt Molecular weight of platinum 195 –
D Diffusion of cisplatin in tissues 2.5  106 cm2/sec Correlation of [59] (normal tissues)
u Extracellular space volume fraction in tissue 0.3 Representative value based on values for various peritoneal tissues from
Ref. [21]
Wrat Weight of rat 200 g [35]
Whuman Weight of human 70 kg –
Vd Volume of distribution of cisplatin in plasma 57,500 cm
2 (human),
(0.2/70)  57,500 cm2 (rat)
Ref. [51] for human; rat value assumed to be scaled
by weight
T1/2
ip Half-life of cisplatin in peritoneal cavity 1.8 hours (human); 1 hour (rat) [40,47] (rat)
kb Rate constant for plasma drug clearance 0.0248 min
1 [51] (see text)
AP Wetted peritoneal surface area 5500 m
2 (human); 200 cm2 (rat) Ref. [6] for human; Ref. [35] for rat
P Microvascular permeability of cisplatin,
or other ultrafilterable Pt species
1.43  104 cm/sec Ref. [28] for sucrose (MW = 342) in frog mesentery
Sv Microvascular surface area per unit volume 70 cm
1 [18]
k Tissue thermal conductivity 2.2  104 g cm/(sec3 jC) [30]
U Density of tissue or plasma 1 g/ml Approximated by density of water
cp Heat capacity of tissue or plasma 4.2  107 cm2/(sec2 jC) [7]
wb Blood perfusion rate 0.001667 hr
1 Ref. [15] from intermediate value between 15 and 18 ml/min/100g
(tumor periphery) and 2–4 ml/min/100g (tumor interior)
Ta Arterial temperature during hyperthermia 37j C Assumed equal to normal body temperature
Flym Lymph flow rate 0.16 ml/hr [20]
k1 Cisplatin cellular pharmacodynamic
model parameter
(for ovarian cancer cells)
0.327 hr1 at 37jC;
0.529 hr1 at 43jC
Ref. [13] fit to data of Ref. [38]; Ref. [34] (see text)
ki Cisplatin cellular pharmacodynamic
model parameter (for ovarian cancer cells)
0.02413 hr1 Ref. [13] fit to data of Ref. [38]
k2 Cisplatin cellular pharmacodynamic
model parameter (for ovarian cancer cells)
3.745 hr1 at 37jC;
28.07 hr1 at 43jC
Ref. [13] fit to data of [38]; Ref. [41] (see text)
k3 Cisplatin cellular pharmacodynamic
model parameter (for ovarian cancer cells)
1.441 hr1 Ref. [13] fit to data of Ref. [38]
m Cisplatin cellular pharmacodynamic
model parameter (for ovarian cancer cells)
1.956 Ref. [13] fit to data of Ref. [38]
A Cisplatin cellular pharmacodynamic
model parameter (for ovarian cancer cells)
1 (mg/ml)1 Ref. [13] fit to data of Ref. [38]
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neglected here. A value for D specific to peritoneal tissues
could not be found, and therefore a general correlation with
molecular weight for tissues was used (Table 1). The possi-
bility that Sv, P, D, and / may vary between tumor and
normal tissues [29] is also neglected here.
The case in which sodium thiosulfate is administered
intravenously to reduce systemic exposure is also simulated.
In this case, the plasma concentration of platinum (the
platinum that is present in active platinum species) is as-
sumed to be zero at all times. In reality, only part of the
systemic platinum may be deactivated, so the model re-
sults may overestimate the effect of sodium thiosulfate
administration.
To determine the significance of convective transport of
drug relative to diffusive transport, the dimensionless groups
u(T/D)1/2 and u(Dk)1/2 were estimated, where u is a typical
fluid velocity out of the cavity, D is the diffusivity of drug in the
tissues, T is the half-life of drug in the cavity, and k is the rate
of uptake by microvessels, cells, protein binding, etc., per
unit volume of tissue. Both these dimensionless groups
represent the ratio of the penetration distance for drug
resulting from convection to that resulting from diffusion.
The first group is for the case in which penetration is limited
by the half-life of the drug in the cavity; the second is for the
case in which penetration is limited by uptake of the drug in
the tissues. It is not clear a priori which of these two factors is
dominant in limiting penetration. The convective velocity u is
estimated as follows. Flessner and Schwab [22] obtained a
fluid loss rate of 5 ml/hr from the rat peritoneal cavity after
infusion of an isotonic solution. The rat peritoneal surface
area is approximately 450 cm2 (Table 1), which implies a flow
velocity of u = 3.1  106 cm/sec. Using the half-life T = 1.8
hours [47] (Table 1) gives u(T/D)1/2 = 0.06. If k is approxi-
mated as the rate of uptake due to microvessels, it can be
estimated as k = PS v = 4.4  10-4 sec-1 , so that u(Dk)-1/2
= 0.03. Based on these arguments, convection of drug was
assumed to be negligible relative to diffusion.
The partial differential equation (Eq. (4)) was solved
simultaneously with the ordinary differential equations
(Eqs. 1, 2, and 5) by discretizing the spatial coordinate x
on the interval 0 < x < L, using central differences. The
Crank–Nicholson method was used to discretize in time.
The resulting system of coupled linear algebraic equations
was solved using the LINPACK package for each time point.
The distance L was taken to be large enough so that plateau
values were unaffected by changing L, except in calculations
where uptake by themicrovasculature was set to zero. In that
case, no plateau was reached at large x, and 10 cm was
taken as sufficiently large. The nodes were spaced more
closely near the cavity surface, the spacing starting at 0.005
cm and increasing with distance from the cavity. Time steps
of 0.005 hour were determined to be sufficiently small so that
halving the step size did not change the results significantly.
Initial conditions were that all concentration variables were 0
at time 0, and the boundary conditions were ce = cip(t ) at x = 0
(the cavity surface), and dce / dx = 0 at x = L. To determine
the peak values of the concentration variables, simulations of
35 hours (or shorter, in the cases where equilibrium spatial
distributions were achieved) were found to be adequate. For
each case considered, the penetration distance d was esti-
mated as the distance at which the peak concentration
approached its plateau value within 1%.
Simulation of Effects of Hyperthermia
In the earliest studies combining hyperthermia with i.p.
drug infusion, heat was administered from extracorporeal
sources [37], but more recent studies have focused on
delivering heat by infusing the peritoneum with a heated
solution [3,50,58]. Both cases are considered here. In the
case of ‘‘regional heating,’’ the entire tissue region under
consideration is assumed to be heated to a uniform temper-
ature of 43jC for a duration td, after which it immediately
cools to 37jC. Effects of transient adjustments in tempera-
ture are neglected. In the case of ‘‘i.p. heating,’’ heat is
assumed to be delivered from the fluid inside the cavity,
which is maintained at either 43jC or 42jC for the duration td,
after which it abruptly drops to 37jC. For this case, the
distribution of temperature with distance from the cavity wall
into the tissuesmust be determined. The bioheat equation [7]
is used here:
BT
Bt
¼ k
qcp
B
2T
Bx2
þ wbðTa  T Þ ð6Þ
with parameters defined in Table 1. The boundary conditions
are that T = 43jC at the peritoneal cavity surface for the
heating duration td, returning to 37jC after this time; and
T!37jC (normal body temperature) as x ! 00. The initial
condition is that T = 37jC for all x. Eq. (6) with these
conditions was solved analytically. A heating duration td of
90 minutes (as in the study of van de Vaart et al. [62]) was
used. Parameter values appropriate for the rat were obtained
from the literature (Table 1).
The effects of hyperthermia on tumor blood flow, which
may include changes in microvascular surface density or
perfusion, are complicated, showing both time dependence
[31,33,45,46] and spatial dependence [1]. Both increases
[44,54,56,57,63] and decreases [14,27,32] in tumor blood
flow have been observed, with some studies reporting dam-
age to supplying vessels [43]. As summarized by Reinhold
and Endrich [53], most experimental tumors show a de-
crease or cessation of blood flow with hyperthermia, but
the evidence is less conclusive for human tumors. Changes
in blood flow are represented in the model by changes in the
perfusion (wb) and in the surface density of perfused vessels
(Sv). Increases in these parameters would lead to decreases
in the penetration distances of heat and drug, respectively,
when delivered locally to the i.p. space. To examine the
possibility of increased penetration distance with hyperther-
mia, we focus here on cases in which blood flow is de-
creased. The cases in which Sv is one tenth the value given
in Table 1 and in which Sv = 0 were therefore included in Eq.
(4) to model possible effects of locally reduced blood supply
in the tumor. In each case, the perfusion parameter wb was
reduced by the same proportion from its value in Table 1.
This assumption of proportional change of perfusion and
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microvascular density was based on observations that
hyperthermia causes reduced blood flow through vessel
damage [14,16,43].
Changes in blood flow in normal peritoneal tissues are
neglected in the present model. In reality, normal tissue
blood flow may increase with heating. Effects of such behav-
ior are considered in the Discussion section. It can be
assumed that most of the peritoneal cavity is lined by normal
tissues, which is therefore the source of most drug uptake by
the circulation. Therefore, the plasma concentration cb(t ) is
estimated in all cases by simultaneous solution of (Eqs. 1, 2,
4, and 5) with Sv = 70 cm
1, corresponding to normal tissues.
To calculate concentration profiles in the tumor, Eq. (4) is
again used, withSv values of 70 cm
1, 7 cm1, and zero. This
procedure neglects any gradients in the transverse direction
(parallel to the cavity surface) due to gradients in blood flow
and other properties between normal and tumor tissues.
Hyperthermia has been found to increase drug uptake
[12,34], which tends to decrease the drug penetration dis-
tance. Kusumoto et al. [34] observed a 1.57-fold increase in
intracellular platinum in HeLa cells following a 30-minute
exposure to 33.2 mM cisplatin at 42.8jC, which, by linear
extrapolation, gives a 1.62-fold increase at 43jC. This was
modeled here by assuming that the uptake parameter k1
increases by a factor of 1.62 at 43jC, so that the total
intracellular concentration is increased by the same factor.
For temperatures between 37jC and 43jC, linear interpola-
tion using the values k1 = 0.327 (at 37jC) and k1 = 0.529
(at 43jC) (Table 1) was used. The factor k1 is related to the
cellular permeability. Because it is believed that heat
increases cell uptake by increasing membrane permeability
[48], the change in uptake at higher temperatures is logically
represented by increasing the value of k1.
Several studies have shown that heat not only causes
greater cellular uptake of drugs, but also higher cytotoxicity
at the same level of intracellular drug [24,34]. Using colon
carcinoma cells, Los et al. [41] measured cytotoxicity versus
cisplatin concentration, for a 1-hour drug exposure, with and
without hyperthermia. At 5 mg/ml cisplatin, survival fraction
decreased by a factor 130 from 0.13 at 37jC to 0.001. The
effect of temperature on cytotoxicity was represented here
by assuming that the parameter k2, representing the rate of
DNA binding, increases with temperature, so as to decrease
survival fraction by a factor of 100 with heating at an
extracellular concentration of 5 mg/ml cisplatin and 1-hour
exposure. In reality, the effects of heating may result from
changes in both DNA adduct formation and adduct process-
ing [25]. Here, the changes in k2 are assumed to represent
the combined effects of both processes. Under these
assumptions, k2 was estimated to increase from 3.745 hr
1
at 37jC to 28.1 hr1 at 43jC. Linear interpolation between
these two values was used to determine k2 as a function of
temperature between 37jC and 43jC. For comparison, the
increase in k2 with heat could also be estimated in a similar
manner from the data of Hettinga et al. [25] for murine Ehrlich
ascites cells, giving 25.5 hr1 at 43jC, close to the estimate
of 28.1 hr1 obtained from the Los et al. data. The latter value
was used in simulations here.
Several other simplifying assumptions were made. In
simulations involving time-dependent temperature changes,
the values of k1 and k2 were assumed to depend only on the
instantaneous temperature, and any time-delayed effects of
temperature changes were not included. Protein binding of
cisplatin in the tissues was neglected. The peritoneum itself
was considered to be identical to the adjacent tissues in
terms of transport properties. Some researchers have
assigned a special resistance to this membrane [55], but
Flessner [17] concluded that ‘‘the peritoneum is similar to the
underlying tissue with respect to its transport resistance to
small solutes.’’ Also, it was assumed that the cellular uptake
of all tissues adjacent to the cavity could be modeled using
the cellular pharmacokinetics of ovarian carcinoma cells. In
actuality, some of the cells in this region will be normal, and
therefore may have different cellular drug uptake. Finally, the
lymph flow coming directly from the cavity is assumed to
instantly enter the circulation, whereas in reality, there is a
time delay. However, the lymph flow term was found to have
only a very small effect on the plasma concentration.
Results
Drug Penetration and Cell Survival without Hyperthermia
Figure 1 shows experimental values of plasma concen-
tration of platinum for i.p. infusion from Ref. [40], together
with the values predicted by the present model. The agree-
ment is satisfactory. Further simulations were performed
for values of microvascular surface density other than
Sv = 70 cm
1, and predicted values then agreed less well
with the experimental values.
Figure 2 shows the predicted variation of peak extracel-
lular and bound intracellular drug levels, and of cell survival
fraction with distance into the tissues. The peak value is
reached at different times at different locations, so these
curves do not represent profiles at any single instant in time.
Except for the case of no perfusion, both concentrations
approach plateau values with increasing distance, repre-
senting supply from the systemic circulation. With normal
Figure 1. Plasma concentration of (ultrafilterable) platinum after i.p. infusion.
Line: theoretical model for ovarian carcinoma cells. Filled circles: exper-
imental data for rat from Ref. [40].
Model for Intraperitoneal Cisplatin Delivery El-Kareh and Secomb 121
Neoplasia . Vol. 6, No. 2, 2004
perfusion, the penetration depth as defined above is 0.48
mm. The penetration distance based on extracellular con-
centration is the same. Beyond this distance, the tissue
receives drug essentially only from the circulation. Although
normal perfusion (wb = 0.001667 hr
1, Sv = 70 cm
1 ) is
expected in the absence of heating, results for low perfused
vascular density (wb = 0.0001667 hr
1 , Sv = 7 cm
1) and
no perfusion (wb = Sv = 0) are included for comparison. With
reduced perfusion, the penetration depth increases to
1.5 mm. Conversely, increasing tumor blood flow causes
decreased penetration distance (results not shown). In the
absence of perfusion, a penetration distance for extracellu-
lar drug as defined earlier cannot be estimated because no
plateau level of concentration is reached. In that case, the
peak extracellular level of drug is higher than that achieved
by systemic delivery (normal perfusion curve) for a depth of
up to about 1.5 mm, but is lower beyond this distance
(Figure 2A). Corresponding behavior is seen for the peak
bound intracellular concentration (Figure 2B) and the sur-
vival fraction (Figure 2C). Figure 2 also shows the effect of
systemic sodium thiosulfate administration, which has been
proposed as a method to decrease systemic toxicity of the
therapy by deactivating the drug in the circulation. In this
case, drug levels rapidly decrease to zero with distance into
tissues because systemic delivery is suppressed.
Drug Penetration and Cell Survival with Hyperthermia
Figure 3 shows results corresponding to those in Figure 2
for the case of regional heating, in which all tissues adjacent
to the cavity are heated to 43jC for the duration of hyper-
thermia, td = 90 minutes [3], after which they return to 37jC.
Results for normal perfusion without heat (Figure 2) are
included for comparison. The distribution of peak extracellu-
lar concentration (Figure 3A) is virtually unaffected by heat-
ing, showing that the increased cellular uptake does not
significantly decrease the penetration distance. Microvascu-
lar uptake is therefore the major factor limiting drug penetra-
tion, and the penetration depth for extracellular drug is 0.48
mm, as before. Effects of reduced or zero perfusion are
similar to those seen in the absence of heating. The in-
creased levels of peak bound intracellular concentration,
relative to those with no heat (Figure 3B), reflect the effects
of both enhanced cellular uptake and enhanced intracellular
binding (increased k1 and k2). Predicted survival fractions
(Figure 3C) are reduced by about two orders of magnitude in
the presence of regional heating.
Figure 4 shows the temperature profile in peritoneal tis-
sues, assuming that heat is delivered by infusing the peritoneal
cavity (i.p. heating) with a solution at temperature 43jC or
42jC [62]. With normal values (at 37jC) of perfusion wb in the
tissues, the profile reaches equilibrium at around 5 minutes.
Significant enhancement of cell kill occurs at temperatures
above about 40jC to 41jC [61], which occur here up to depths
of about 0.5 cm with normal perfusion. With reduced perfusion
(wb one tenth of normal), an equilibrium profile is reached after
about 8 minutes, and the penetration distance of heat is
increased. With no perfusion (wb = 0), no equilibrium is
reached and the depth of penetration of heat increases inde-
finitely with time. Results are shown for 90 minutes of heating.
For reduced and zero perfusion, therapeutically useful temper-
atures (above 40jC) are achieved up to depths of 1 to 2 cm.
In Figure 5, model predictions corresponding to those
in Figure 3 are shown for i.p. heating. Cellular uptake and
Figure 2. Predictions of the mathematical model for rat, with ovarian car-
cinoma cells, without hyperthermia. Solid lines: normal tumor perfusion
(vessel surface density Sv = 70 cm
1). Dashed lines: low tumor perfusion,
represented by reduced surface density (Sv = 7 cm
1). Dashed–dotted lines:
zero tumor perfusion. Dotted lines: with sodium thiosulfate administered
intravenously, assumed to deactivate all circulating cisplatin. (A) Peak extra-
cellular concentration in tumor as a function of position. The peak value is
reached at different times at different points, so this curve is not a
concentration profile at one instant in time. (B) Peak intracellular concen-
tration in tumor as a function of position. (C) Survival fraction of cancer cells.
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intracellular binding are functions of temperature as de-
scribed previously, and results are shown for normal, re-
duced, and zero perfusion. Results for normal perfusion
without heat (Figure 2) are again included for com-
parison. These results show increased intracellular binding
(Figure 5B) and cytotoxicity (Figure 5C) near the peritoneal
surface, resulting from the combined effects of the temper-
ature-dependent changes in pharmacodynamic and trans-
port parameters. At depths of 2 cm or more, concentrations
closely approach the plateau level, and this distance repre-
sents an upper limit on the predicted extent of therapeutic
benefit from i.p. heating.
Discussion
In the present model, the accumulation of drug in the
plasma following i.p. infusion is assumed to result from
uptake by microvessels in tissues adjacent to the peritoneal
cavity. According to Eq. (5), the predicted plasma concen-
tration depends critically on the parameters describing trans-
port and exchange of the drug in the tissues. The agreement
between predicted and observed plasma concentrations of
ultrafilterable platinum (Figure 1) therefore supports the
validity of the assumed model for tissue transport, which is
used to estimate the penetration distance. The results of
Figure 1 were for an assumed value of microvascular surface
density of Sv = 70 cm
1 (Table 1), and agreement is consi-
derably poorer if the value of Sv is changed substantially.
This suggests that this value of Sv is representative, on
average, of the tissues lining the peritoneal cavity. However,
the cavity is lined with a number of different tissues, and local
deviations from this average value may occur.
The model predicts that the penetration distance for drug
diffusing directly from the cavity into the surrounding tissues
is small, on the order of 0.48 mm, for normally perfused
tissue (Figure 2). The basic reason for this result is that, in
perfused tissues, the microvasculature provides a large area
for exchange, and extracellular concentration therefore
tends to be equilibrated with plasma concentration. Drug
diffusing into the tissues at higher concentrations is rapidly
taken up by the microvessels. The plateau levels in Figure 2
at depths beyond roughly 0.48 mm reflect systemic levels.
The estimate of penetration depth given by the formula
(D/k)1/2 [10], with k = PSv and parameter values from
Table 1, is 0.14 mm, comparable to the predictions of the
present model. The theoretical predictions of Flessner et al.
[19] for tissue concentrations of intraperitoneally adminis-
tered sucrose show a comparable penetration distance, as
do the experimental and theoretical concentration profiles for
EDTA of Flessner et al. [21], which level off at about 0.3 to
Figure 3. Predictions of mathematical model as in Figure 2, but with regional
hyperthermia (i.e., all tissues adjacent to the peritoneal cavity heated to a
uniform 43 C). Solid lines: normal tumor perfusion. Dashed lines: low tumor
perfusion. Dashed–dotted lines: zero tumor perfusion. Dotted lines: normal
tumor perfusion without heating, as shown in Figure 2.
Figure 4. Predictions of theoretical model for penetration of heat into the
tumor tissues adjacent to the peritoneal cavity. The cavity is assumed to be at
a constant temperature of either 42jC or 43jC for 90 minutes, after which it
returns to 37jC. The cases of normal, low, and zero tumor perfusion are
shown. Except for the case of wb = 0, all profiles are steady state reached
after approximately 5 to 10 minutes.
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0.4 mm from the peritoneal surface in uterine, liver, and
spleen tissues, and at about 0.5 to 0.6 mm in parietal tissues.
Experimental studies have yielded widely varying esti-
mates of the penetration depth. Ozols et al. [49] compared
i.p. with i.v. delivery of adriamycin in mice. Intense fluores-
cence associated with levels of adriamycin higher than that
achieved by i.v. exposure could be seen only in the outer-
most four to six cell layers of intra-abdominal tumors. This
implies a penetration distance around 0.1 mm, based on a
cell dimension of no more than 20 mm. In a study comparing
i.p. to i.v. delivery of cisplatin in rats, Los et al. [40] measured
levels of platinum in i.p. tumors at 4, 24, and 168 hours after
treatment, for both single cycles and fractionated doses. No
difference was found at 4 and 24 hours. At 168 hours, with a
fractionated dose, the amount of platinum per weight of
tumor tissue was found to be significantly higher for i.p. than
that for i.v. therapy up to a distance of 1.5 mm into the tumor.
However, by 24 hours after i.p. therapy, plasma concentra-
tions of platinum were higher than concentrations in the
peritoneal cavity, so it is not clear that the apparent regional
advantage at 168 hours could have resulted from diffusion
directly into tissues from the i.p. space. Los et al. [42]
analyzed the spatial distribution of platinum 24 hours after
the last injection of drug, and found that levels at 1 mm were
substantially elevated over levels at 3 mm. Los and McVie
[39] summarize other studies as giving estimates for the
penetration depth of cisplatin in the 1 to 3 mm, or 2 to 2.5 mm
range. One possible explanation for the observation of
penetration depths larger than predicted here is that micro-
vascular surface density levels in the vicinity of these nod-
ules may be lower than assumed (Sv = 70 cm
1). However,
as already mentioned, the assumed value is consistent with
drug concentrations observed in plasma. Another possibility
is that spatial gradients in the volume fraction u of extracel-
lular space [21] significantly affect the concentration distri-
bution. Here, u is held constant and this possible effect is
excluded.
The possible effects of hyperthermia on drug distribution
and cytotoxicity in peritoneal tissues are explored in
Figures 2, 3, and 5. As discussed above, some studies have
indicated decreased tumor blood flow, or even vascular
stasis, in tumors in rodent models with high heat [53,63].
Figure 2 shows that eliminating microvascular uptake, which
may be at least partially achievable by hyperthermia or by an
agent that targets tumor vasculature, such as combrestatin
[26], would lead to reduced tumor cell survival up to a depth
of about 1.7 mm, but to increased survival beyond this depth.
If high levels of cisplatin could be maintained for a longer time
in the cavity in the absence of microvascular uptake, the drug
would be able to diffuse out further. However, this might
result in unacceptable host toxicity. Hyperthermia has also
been shown to result in increased cell uptake [12]. Although
this might be expected to result in a decreased penetration
distance, the model results (Figure 3) indicate no significant
change in penetration distance.
Several authors [5,41,62] have stated that the penetration
depth of cisplatin is increased under hyperthermic condi-
tions. Possible mechanisms by which hyperthermia could
affect drug penetration are effects on convection and diffu-
sion in tissues, cell uptake of drug, tumor blood flow, and
vascular permeability to drug. Because diffusion is dominant
over convection, changes in convection, due for example to
tissue expansion or degradation of the extracellular matrix,
are unlikely to make a significant difference. Large changes
in tissue diffusivity with heating from 37jC to 43jC are also
unlikely. Figure 3 shows that changes in cell uptake with heat
have negligible effect on penetration distance of cisplatin,
Figure 5. Predictions of mathematical model as in Figure 2, but with i.p.
hyperthermia, achieved by infusing the peritoneal cavity with a solution at
43jC. Solid lines: normal tumor perfusion. Dashed lines: low tumor perfusion.
Dashed–dotted lines: zero tumor perfusion. Dotted lines: normal tumor
perfusion without heating, as shown in Figure 2.
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although the effect might be significant for other drugs that
are taken up more rapidly by cells. The remaining two
possibilities (changes in microvascular density or in micro-
vascular permeability) are mathematically equivalent be-
cause they appear in the model only in the factor PSv in
Eq. (6). Figure 3 shows that a decrease in this parameter can
increase the penetration distance of the drug, at the expense
of a reduction in drug levels beyond the penetration distance.
However, tumor microvascular permeability has been ob-
served to increase with hyperthermia above 43jC [36],
whereas evidence for decreased perfusion in hyperthermia
is not conclusive [53,57,63].
For the case of i.p. heating, the present results (Figure 5)
suggest an alternative explanation for the observation of
increased penetration depth with hyperthermia. Penetration
of heat into the tissues (Figure 4) results in a region of
increased drug uptake that extends 1 to 2 cm into the tissues.
This phenomenon may underlie the observation [62] of
increased levels of platinum–DNA adducts at depths greater
than 3 mm in human patients, relative to control cells distant
from the peritoneum, when i.p. cisplatin was accompanied by
i.p. hyperthermia. Thus, the apparent increase in penetration
distance may reflect penetration of heat, leading to en-
hanced drug uptake, without any increase in extracellular
drug levels (Figure 5A).
Sodium thiosulfate, which deactivates cisplatin, has
been administered intravenously [3,11,23] concurrently with
i.p. therapy (with and without hyperthermia) on the grounds
that it reduces systemic exposure. As shown in Figure 2,
this treatment would have the effect of greatly reducing
drug levels in tissues at points beyond the penetration
distance of about 0.48 mm, where the tissues receive
the drug only from the circulation. Despite studies showing
that it has the potential to reduce host toxicities, sodium
thiosulfate has not been generally adopted for clinical
use because of concerns that it also reduces anticancer
effects [4]. The present results suggest that simultaneous
administration of thiosulfate with cisplatin would not be
advantageous.
The results presented here are based on parameter
values for the rat, some of which may differ from those for
humans. The microvascular density, cellular uptake, and
diffusivity of cisplatin in the tissues adjacent to the cavity
can be assumed to be of similar magnitude for both
species. The peritoneal half-life of cisplatin for humans
[47] is similar to that for rats [40]. Penetration distances
for the drug should therefore be comparable in both
species. The ratio of human to rat blood volume is
approximately equal to the weight ratio, 70 kg / 0.2 kg
= 350, whereas the ratio of the human peritoneal surface
area to that of the rat is 5500 cm2 / 200 cm2 = 28
(Table 1). If penetration distances are assumed equal, the
total uptake of cisplatin is therefore 28 times larger for
humans, assuming the same i.p. concentration. Because
the blood volume is 350 times larger, plasma concentra-
tions are expected to be lower, leading to lower plateau
concentrations and higher plateau survival fractions (Fig-
ure 2). This assumes that the ratio of volume of distribu-
tion to plasma volume is approximately the same for the
rat and humans.
Several simplifying assumptions were made in the model
presented here. A kinetic model of cellular cisplatin uptake
developed for ovarian tumor cells was used not only within
the tumor but also for all normal tissues surrounding the
peritoneum. However, cellular drug uptake was found to
have only a slight effect on concentration profiles, so this
assumption does not lead to significant errors. Another
model assumption is that blood flow in the normal peritoneal
tissues remains unchanged with heat. A heat-induced in-
crease in blood flow in normal tissues during the period of i.p.
drug exposure might result in increased plasma drug levels,
if associated with an increase in perfused vessel density
(Sv). Such an effect would increase the plateau values of
concentration (Figures 2, 3, and 5), but would not affect the
penetration distance. In practice, if heating resulted in in-
creased plasma levels, a reduction in the applied dose would
probably be needed to avoid increased systemic toxicity, so
using the same plasma concentration function for the heated
and nonheated cases would be appropriate.
In summary, the model predicts that the distance that
cisplatin diffuses into peritoneal tissues is short, about 0.48
mm, and that this distance is limited by the rate of microvas-
cular uptake. Beyond this distance, the drug reaches tissues
primarily through the circulation. The model suggests that
hyperthermia administered locally, in the form of a heated
drug solution infused into the peritoneal cavity, does not
cause increased penetration of the drug into the tissues.
However, cell kill may be locally increased up to a distance
on the order of 1 cm into the tissues, due to penetration of
heat and the resulting increases in cellular uptake and
toxicity of drug. It may therefore be therapeutically advanta-
geous to combine i.v. drug administration with delivery of
hyperthermia by i.p. infusion.
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